Lineage Cell Therapeutics, Inc. (LCTX) stock
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Earnings
Lineage Cell Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Lineage Cell Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | $1.50M | -59.5% | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $1.10M | -60.7% | -$0.03 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026during market hours | $1.70M | +13.3% | -$0.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026during market hours | $6.60M | +127.6% | $0.00 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $3.70M | -2.6% | -$0.13 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025during market hours | $2.80M | +100.0% | -$0.13 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025during market hours | $1.50M | +7.1% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025during market hours | $2.90M | +38.1% | -$0.02 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024during market hours | $3.80M | +216.7% | -$0.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $1.40M | -56.3% | -$0.03 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | $1.40M | -41.7% | -$0.04 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024during market hours | $2.10M | +10.5% | -$0.03 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | $1.20M | -60.0% | -$0.04 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023during market hours | $3.20M | – | -$0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | $2.40M | -53.8% | -$0.03 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023during market hours | $1.90M | +58.3% | $0.03 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022during market hours | $3.00M | +30.4% | -$0.04 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022during market hours | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022during market hours | $5.20M | – | -$0.04 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022during market hours | $1.20M | – | -$0.17 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | $2.30M | – | -$0.05 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 5, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Lineage Cell Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Lineage Cell Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Lineage Cell Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEResults
- Results
- Results
- Results
- LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEResults
- Update
- Results
- Results
- Update
- Update
- Results
- LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEResults
- Results
See a number that looks wrong?